GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » 14-Day RSI

Ascletis Pharma (HKSE:01672) 14-Day RSI : 32.13 (As of May. 31, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-05-31), Ascletis Pharma's 14-Day RSI is 32.13.

The industry rank for Ascletis Pharma's 14-Day RSI or its related term are showing as below:

HKSE:01672's 14-Day RSI is ranked better than
87.22% of 1565 companies
in the Biotechnology industry
Industry Median: 44.84 vs HKSE:01672: 32.13

Competitive Comparison of Ascletis Pharma's 14-Day RSI

For the Biotechnology subindustry, Ascletis Pharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascletis Pharma's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's 14-Day RSI falls into.



Ascletis Pharma  (HKSE:01672) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascletis Pharma  (HKSE:01672) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Ascletis Pharma 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma (HKSE:01672) Business Description

Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.
Executives
Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason 2101 Beneficial owner
Wu Judy Hejingdao 2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd. 2201 Interest of corporation controlled by you
Fu Wei 2201 Interest of corporation controlled by you
Tf Capital Ii Ltd. 2201 Interest of corporation controlled by you
Tf Capital, Ltd. 2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited 2201 Interest of corporation controlled by you
Yang Dan 2201 Interest of corporation controlled by you

Ascletis Pharma (HKSE:01672) Headlines

No Headlines